www.scottishmedicines.org.uk

Healthcare Improvement Scotland | SMC Advice on new medicines

Product update
SMC2510

upadacitinib 15mg, 30mg, and 45mg prolonged-release tablets (Rinvoq®)

AbbVie Ltd

09 September 2022

The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and, following review by the SMC executive, advises NHS Boards and Area Drug and Therapeutics Committees on its use in NHSScotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

upadacitinib (Rinvoq®) is accepted for use within NHSScotland.

Indication under review: for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, lost response or were intolerant to either conventional therapy or a biologic agent.

Upadacitinib offers an additional treatment choice in the therapeutic class of janus kinase inhibitors.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

This assessment is based on data submitted by the applicant company up to and including 26 August 2022.

Chairman, Scottish Medicines Consortium

Published 10 October 2022